-- 週四，生質燃料原料期貨價格漲跌互現，其中豆油期貨價格再次觸及合約高點，而大豆期貨價格則從早盤低點反彈，遠期合約價格小幅上漲。 芝加哥期貨交易所（CBOT）7月大豆期貨合約週四收跌0.13%，報每蒲式耳11.95美元；CBOT 7月豆油期貨合約收漲0.57%，報每磅74.54美分。 週三，紐約商品交易所（Nymex）6月乙醇期貨合約收漲3.39%，報每加侖2.06美元。 DTN分析師雷特蒙哥馬利表示，小麥期貨市場的避險情緒蔓延至其他農產品期貨市場。 蒙哥馬利在每日報告中指出：“玉米市場疲軟的局面蔓延開來，而大豆市場則更具韌性，交易員們仍願意等待5月份特朗普/習近平峰會的結果，然後再對長期價格走勢做出判斷。” 美國眾議院通過了一項「精簡版」農業法案。原本，E15農村國內能源委員會提出的全年全國性E15燃料提案也應同時進行投票表決。 經過持續的談判，E15提案的投票將於5月13日國會休會後進行。 週四，美國農業部報告稱，截至4月23日當週，2025/26年度大豆出口銷量增加950萬蒲式耳（約25.81萬噸），而2026/27年度銷量增加10萬蒲式耳（約3000噸）。 上週出口量為 2,240 萬蒲式耳，高於美國農業部為實現 2025/26 年 15.4 億蒲式耳的出口預估目標所需的每週 1750 萬蒲式耳。目前，2025/26 年大豆出口承諾總量為 14.25 億蒲式耳，比一年前下降了 18%。
Related Articles
Research
Research Alert: Bio: Q1 Results Above Estimates Despite Meaningful Sales/margin Compression
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BIO delivered Q1 results showing pressure across both segments, with revenue of $592.1M growing 1.1% Y/Y (~$3M above consensus) but declining 4.2% currency neutral. Adjusted EPS of $1.89 fell 25.6% Y/Y yet beat consensus by $0.10, while operating margin deteriorated 420 bps to 6.6% from 10.8% in the prior year. Both Life Science and Clinical Diagnostics segments experienced currency neutral declines due to ongoing academia weakness and Middle East conflicts. Management lowered 2026 guidance, expecting currency neutral revenue of -3.0% to +0.5% growth (down from +0.5% to +1.5%) and operating margin of 10.0%-12.0% (vs. prior 12.0%-12.5%). Despite operational headwinds, BIO maintained strong cash generation with $78.1M in FCF and repurchased ~176K shares. The company's balance sheet remains healthy, with $1.56B in cash and short-term investments, providing financial flexibility amid challenging market conditions, in our view.
$BIO
Asia
ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue
ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.
$ASX:RMD
Research
Research Alert: Gddy: Strong Profitability Metrics Offset By Continued Revenue Headwinds
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GDDY posted Q1 2026 revenue of $1.2B (+6%), in line with consensus, with EPS of $1.60 beating estimates of $1.52 despite booking deceleration to +2.7% from +5% in Q4. A&C segment growth of +11.6% to $498M showed resilience but continued moderating, while Core Platform remained sluggish at +2.8%. We view booking weakness as concerning given competitive pressures and small business spending constraints that raise questions about growth sustainability. Management reaffirmed 2026 revenue guidance of $5.195B-$5.275B (~6% growth), reflecting limited visibility into booking improvement. However, we see encouraging AI monetization signs with ARPU growth of +9.3% to $246 and Airo AI Builder achieving multi-million dollar annualized bookings within weeks of beta launch. We believe GDDY's impressive margin expansion with NEBITDA margins reaching 32.6% (+210 bps) demonstrates operational discipline, though sustaining A&C growth above 10% remains critical for investor confidence.
$GDDY